ICA Foundation                     LNG IUS                     Projects                     Application

About the LNG IUS

How does the LNG IUS work?

How effective is the LNG IUS?

Client Information



Photo: Sarah Engebretsen, courtesy of the Population Council

Levonorgestrel Intrauterine System (LNG IUS)


The levonorgestrel intrauterine system (IUS) is a contraceptive method made of plastic, and shaped like the letter “T”, placed inside the uterus. Inside, it contains a synthetic female hormone, levonorgestrel, which is released slowly into the uterus (womb), helping to prevent pregnancy. This hormone acts like the natural hormone progesterone and is widely used in other contraceptive methods, such as implants and oral contraceptive pills.

 
Brief facts
  • Over the first year of use, the pregnancy rate for LNG IUS users is 1 to 3 per 1,000 women, a rate less than 1%
  • The LNG IUS is a safe method of contraception, comparable to sterilization
  • The LNG IUS provides a lower and steadier dose of hormones than oral contraceptive pills
  • The LNG IUS is easily inserted and easily removed
  • Fertility returns quickly upon removal of the LNG IUS device
  • Use of LNG IUS may help shorten, lighten or even eliminate menstrual bleeding
 
Product Development
 

The Levonorgestrel Intrauterine System (LNG IUS) was developed by Population Council and Bayer Schering Pharma Oy and is currently distributed by Bayer Schering Pharma in the private market. The LNG IUS is now also available to the public-sector audience, through various mediums of distribution.

The development of the LNG IUS began in the late 1970s at the Population Council, with the aim of creating a contraceptive device combining the beneficial features of both oral contraceptives and intrauterine devices. Today clinical data is available for over 13,000 women-years of product use, demonstrating high efficiency and acceptance of the LNG IUS.

 
Product Description
 

The Levonorgestrel Intrauterine System (LNG IUS) was developed by Population Council and Bayer Oy and is currently distributed by Bayer in the private market. The LNG IUS is also available in the public-sector and non-profit market through the ICA Foundation.

The development of the LNG IUS began in the late 1970s at the Population Council, with the aim of creating a contraceptive device combining the beneficial features of both oral contraceptives and intrauterine devices. Today clinical data is available for over 13,000 women-years of product use, demonstrating high efficiency and acceptance of the LNG IUS.


LNG IUS added in the WHO Essential Medicines List


In 2015 the World health Organization added the LNG IUS to its Essential Medicines List (EML). Countries may in turn add the LNG IUS to their own EMLs following the positive WHO assesment. The WHO added guidance to its Medical Eligibility Criteria to ensure that healthcare providers understand the method and have the appropriate knowledge to counsel clients about its adoption and use.

www.who.int



         Board of Trustees         Contact         Disclaimer         Sitemap